GlassScriptPhysician profile
Randall A Kavalier
NPI 1003884107
$15,335.34
in general payments reported to CMS, 2019-2025
18 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $373 · 2021: $909 · 2022: $6,956 · 2023: $5,895 · 2024: $337 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,480 · Food and Beverage: $1,531 · Consulting Fee: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,480.00 |
| Food and Beverage | $1,531.31 |
| Consulting Fee | $640.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $12,763.47 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $494.91 | 2019-2025 | Rexulti |
| Lundbeck LLC | $334.03 | 2019-2025 | Rexulti, Brintellix |
| Adlon Therapeutics L.P. | $285.19 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $275.15 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $263.09 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $262.97 | 2019-2024 | |
| Neos Therapeutics, LP | $200.98 | 2019-2022 | |
| Tris Pharma INC | $200.52 | 2019-2025 | Dyanavel Xr |
| Shire North American Group INC | $60.67 | 2019 | |
| Vertical Pharmaceuticals, LLC | $47.73 | 2019 | |
| Eisai INC. | $38.42 | 2021 | |
| Idorsia Pharmaceuticals US INC | $30.32 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $21.08 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.63 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $14.57 | 2023 | Auvelity |
| Alkermes, INC. | $13.62 | 2021 | |
| Neuronetics, INC. | $8.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Kavalier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.